Boudhabhay [7]
|
2018
|
60
|
M
|
multiple myeloma
|
cornea, kidney
|
2 years
|
IgGkappa
|
bortezomib-lenalidomide-dexamethasone
|
PR
|
NO
|
End stage renal failure
|
Wu [8]
|
2017
|
48
|
M
|
multiple myeloma
|
kidney
|
Unknown
|
IgGkappa
|
bortezomib-cyclophosphamide-dexamethasone
|
VGPR
|
NO
|
End stage renal failure
|
Aline-Fardin[9]
|
2015
|
69
|
M
|
monoclonal gammopathy
|
mesenteric panniculitis, lympho node, kidney
|
6 months
|
LC kappa
|
bortezomib-DXM
|
VGPR
|
YES
|
Persistent remission (12 months)
|
Baird [10]
|
2015
|
53
|
F
|
lymphoplasmocytic lymphoma
|
lung, mediastinal lymph node, bone marrow
|
18 months
|
IgM lambda
|
bortezomib-cyclophosphamide-dexamethasone-rituximab
|
VGPR
|
YES
|
Remission
|
Hu [11]
|
2012
|
48
|
F
|
multiple myeloma
|
spleen, bone marrow
|
2 years
|
IgGkappa
|
bortezomib-thalidomide-dexamethasone-rituximab
|
VGPR
|
YES
|
Remission
|
Robak [12]
|
2002
|
54
|
M
|
lymphoplasmocytic lymphoma
|
spleen, bone marrow
|
1 year
|
IgAkappa
|
ritixmab
|
PR
|
NO
|
Pancytopenia
|